Reengineering Medicines Development
Cutting development time and cost, to bring affordable medicines to patients more quickly
Developing new medicines is lengthy, costly and high risk and drives up prices of new medicines, reducing access and delaying introduction of important new therapies.
Vermilion Life Sciences is different. We Reengineer Medicines Development to reduce development times and costs. We build partnerships between companies, regulators, payers and patients to improve the value of new medicines and speed adoption, making them available more quickly, at lower cost with greater certainty in use.
As a member of the UK Government's Office for Life Sciences Expert Advisory Group on Innovative Medicines, and leading a work stream on the Accelerated Access Review, (Final report published here) we showed how all parties working together has the potential to improve development efficiency and effectiveness, to speed decision making and access to new medicines.
Please contact us to see how we can cut your development costs and time while improving the likelihood of access.
Please explore the links above to read more about Vermilion Life Sciences.
A member of the
© 2014 - 2022
ReMedDev® is a TM of
Vermilion Life Sciences Ltd